Uganda is one of the 30 WHO-designated countries with a high burden of TB/HIV. In 2019, the estimated incidence rate for TB was 200 per 100,000 population and the mortality rate was 35 per 100,000 population [1]. In 2019, 65,897 TB cases were notified. In the same year, the WHO estimated that 1% of new cases and 12% of previously treated cases were MDR/RR-TB cases. In 2017, MDR/RR-TB treatment was initiated in 384 patients, of which 74% were successfully treated.
STREAM Stage 2 is recruiting at one site in Kampala, Uganda, in partnership with the Makerere University Lung Institute and the Mulago National Referral Hospital. The Lung Institute was established in the Makerere College of Health Sciences to specialize in fighting lung diseases such as tuberculosis. In addition, Makerere University has significant experience implementing clinical trials as part of initiatives including Drugs for Neglected Diseases Initiative.
The Mulago Hospital was founded in 1913 and is the main national regional hospital for the entire country and a teaching hospital for the Makerere College of Health Science. With over 1700 hospital beds, they seek to provide super-specialized healthcare, to provide training and to conduct operational research in line with Ministry of Health requirements. The Hospital’s capacity for conducting clinical trials, its high volume of patients, and its expertise in managing tuberculosis are factors that contributed to selecting this partner in Uganda.
The STREAM site in Uganda recruited 56 participants for STREAM Stage 2.
[1] Mortality rate includes HIV-positive TB cases
